Overview

Eliquis Regulatory Post Marketing Surveillance

Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
0
Participant gender:
All
Summary
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban
Criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Patients ≥19 years of age

- Adult patients who are diagnosed with nonvalvular atrial fibrillation and are
initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic
embolism

- Patients with evidence of a personally signed and dated informed consent document
indicating that the patient (or a legally acceptable representative) has been informed
of all pertinent aspects of the study

Exclusion Criteria:

- Receiving Eliquis treatment for an indication that is not approved in Korea

- Contraindicated for the use of Eliquis as described in the Korean label